1. Home
  2. LEGN vs BFAM Comparison

LEGN vs BFAM Comparison

Compare LEGN & BFAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • BFAM
  • Stock Information
  • Founded
  • LEGN 2014
  • BFAM 1986
  • Country
  • LEGN United States
  • BFAM United States
  • Employees
  • LEGN N/A
  • BFAM N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • BFAM Other Consumer Services
  • Sector
  • LEGN Health Care
  • BFAM Consumer Discretionary
  • Exchange
  • LEGN Nasdaq
  • BFAM Nasdaq
  • Market Cap
  • LEGN 5.4B
  • BFAM 7.1B
  • IPO Year
  • LEGN 2020
  • BFAM 1997
  • Fundamental
  • Price
  • LEGN $28.95
  • BFAM $129.36
  • Analyst Decision
  • LEGN Strong Buy
  • BFAM Buy
  • Analyst Count
  • LEGN 12
  • BFAM 8
  • Target Price
  • LEGN $77.09
  • BFAM $139.13
  • AVG Volume (30 Days)
  • LEGN 1.9M
  • BFAM 560.0K
  • Earning Date
  • LEGN 05-13-2025
  • BFAM 05-05-2025
  • Dividend Yield
  • LEGN N/A
  • BFAM N/A
  • EPS Growth
  • LEGN N/A
  • BFAM 93.82
  • EPS
  • LEGN N/A
  • BFAM 2.77
  • Revenue
  • LEGN $728,303,000.00
  • BFAM $2,728,831,000.00
  • Revenue This Year
  • LEGN $64.21
  • BFAM $9.64
  • Revenue Next Year
  • LEGN $53.69
  • BFAM $7.16
  • P/E Ratio
  • LEGN N/A
  • BFAM $46.66
  • Revenue Growth
  • LEGN 112.46
  • BFAM 9.71
  • 52 Week Low
  • LEGN $27.34
  • BFAM $100.59
  • 52 Week High
  • LEGN $60.87
  • BFAM $141.90
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 41.56
  • BFAM 57.47
  • Support Level
  • LEGN $28.13
  • BFAM $127.28
  • Resistance Level
  • LEGN $29.31
  • BFAM $132.99
  • Average True Range (ATR)
  • LEGN 1.63
  • BFAM 3.30
  • MACD
  • LEGN 0.03
  • BFAM 0.52
  • Stochastic Oscillator
  • LEGN 27.01
  • BFAM 64.47

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About BFAM Bright Horizons Family Solutions Inc.

Bright Horizons Family Solutions Inc provider of early education and child care, family care solutions, and workforce education services that help working families and client employees personally and professionally. It provides services under multi-year contracts with employers that offer early education and child care, back-up care, and educational advisory services as part of their employee benefits package. The company has three business segments; full-service center-based child care, backup care, and educational advisory services. The majority of the revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, and Others.

Share on Social Networks: